Cargando…

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY

Detalles Bibliográficos
Autores principales:	Gordon, L. I., Hoda, D., Shi, L., Guo, S., Liu, F. F., Braverman, J., Dubowy, R., Peng, L., Sehgal, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429202/ http://dx.doi.org/10.1097/01.HS9.0000849696.81993.90

Ejemplares similares

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel
por: Olson, N. Eric, et al.
Publicado: (2023)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
por: Mirza, Abu-Sayeef, et al.
Publicado: (2023)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2022)

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
por: Maloney, David G., et al.
Publicado: (2021)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2022)

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
por: Abramson, Jeremy S., et al.
Publicado: (2023)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL
por: Rasheed, Yusuf, et al.
Publicado: (2023)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
por: Strati, P., et al.
Publicado: (2022)

Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
por: Parker, Christopher, et al.
Publicado: (2023)

Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1
por: Salles, Gilles, et al.
Publicado: (2021)

Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
por: Cartron, Guillaume, et al.
Publicado: (2022)

Charité 1710–1985
por: Granshaw, Lindsay
Publicado: (1986)

AGREEMENT K1710
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2010)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

On the B(1235) and $\rho$ (1710) production on nuclei
por: Arnold, R, et al.
Publicado: (1973)

Les normes de gestion de réseau à l'ISO
por: Lecerf, Christian, et al.
Publicado: (1993)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
por: Derigs, P., et al.
Publicado: (2022)

ST1710–DNA complex crystal structure reveals the DNA binding mechanism of the MarR family of regulators
por: Kumarevel, Thirumananseri, et al.
Publicado: (2009)

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
por: Strati, Paolo, et al.
Publicado: (2023)

Abraham Trembley of Geneva; Scientist and Philosopher, 1710-1784
por: Forbes, Thomas R.
Publicado: (1954)

Regulation of cel Genes of C. cellulolyticum: Identification of GlyR2, a Transcriptional Regulator Regulating cel5D Gene Expression
por: Fendri, Imen, et al.
Publicado: (2013)

El monopolio estatal del mercurio en el México colonial, 1550-1710 /
por: Lang, M. F. (Mervyn F.)
Publicado: (1977)

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
por: Hutchings, Martin, et al.
Publicado: (2023)

William Heberden the elder (1710-1801): aspects of his London practice.
por: Heberden, E
Publicado: (1986)

Mar cel Levi
por: Baltesen, Frits
Publicado: (2021)

P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US)
por: Locke, F., et al.
Publicado: (2022)

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
por: Perez, Ariel, et al.
Publicado: (2022)

The spin of the $f_{J}(1710)$ and new effects observed in the WA102 experiment
por: Kirk, A.
Publicado: (1999)

1710. Profiling Patients with Rare Mucormycosis Infections Using Real-world Data
por: Sung, Anita H, et al.
Publicado: (2019)

1710. Clostridioides difficile Bundle Implementation Reduces Unnecessary Testing in Pediatric Patients
por: Sietsema, Lydia, et al.
Publicado: (2023)

Abstract: 17.10 Development Of A Novel Digital Image System In Plastic Surgery
por: Bonde, Christian, et al.
Publicado: (2017)

Pathogenic Carboxyl Ester Lipase (CEL) Variants Interact with the Normal CEL Protein in Pancreatic Cells
por: Dalva, Monica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8chfn9cd4ofbokf8mm5bvnca6g